Squamous non-small cell lung cancer
Conditions
Interventions
experiment group:albumin-bound paclitaxel combined with cisplatin
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Men and women, >=18 years of age; 2. Histologically or cytologically confirmed tissue type squamous cell carcinoma; 3. Surgically resectable NSCLC of IB-IIIB; 4. Patients who have not previously received initial treatment for chemotherapy or radiation therapy; 5. ECOG score = 3 months; 7. Subjects of childbearing age must agree to take effective contraceptive measures during the trial; The serum or urine pregnancy test for women of childbearing age 72 hours before the start must be negative; 8. Subjects are well compliant, able to undergo treatment and follow-up, and voluntarily comply with the study; 9. Subjects voluntarily signed informed consent.
Exclusion criteria
Exclusion criteria: 1. N3 or M1; 2. There are uncontrolled serious medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled high blood pressure, uncontrolled infection, active peptic ulcer, etc.; 3. Dementia, mental state changes, or any mental illness that interferes with understanding or making informed consent or completing a questionnaire; 4. Subjects with >= 2 peripheral neuropathy according to CTCAE V5.0; 5. A history of allergies or hypersensitivity reactions to any of the therapeutic ingredients; 6. Have a malignant tumor other than NSCLC in the past 5 years, except for adequately treated basal cells or squamous cell skin cancer, localized prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery ; 7. Physical examination and laboratory test results are abnormal: a) Hematological dysfunction is defined as: i) Neutrophil absolute count: 1.5 times the upper limit of normal (ULN); ii) Aspartate aminotransferase and alanine aminotransferase > 2.5 times ULN; c) Renal dysfunction: serum creatinine > 1.5 times ULN, or calculated creatinine clearance < 50ml / min; 8.Combine other anti-cancer drug treatments; 9. Have received any other test drug treatment or participated in another interventional clinical trial within 30 days prior to screening; 10. The investigator believes that it is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative pathological complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Surgical complete resection rate;safety; | — |
Countries
China
Contacts
Public ContactYue Yang
Department of Thoracic Surgery II, Beijing Cancer Hospital
Outcome results
None listed